SE9802080D0 - Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein - Google Patents

Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein

Info

Publication number
SE9802080D0
SE9802080D0 SE9802080A SE9802080A SE9802080D0 SE 9802080 D0 SE9802080 D0 SE 9802080D0 SE 9802080 A SE9802080 A SE 9802080A SE 9802080 A SE9802080 A SE 9802080A SE 9802080 D0 SE9802080 D0 SE 9802080D0
Authority
SE
Sweden
Prior art keywords
treatment
bowel syndrome
irritable bowel
functional dyspepsia
pharmaceutical composition
Prior art date
Application number
SE9802080A
Other languages
English (en)
Swedish (sv)
Inventor
Per Holmstroem
Suad Efendic
Original Assignee
Hellstroem
Suad Efendic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hellstroem, Suad Efendic filed Critical Hellstroem
Priority to SE9802080A priority Critical patent/SE9802080D0/xx
Publication of SE9802080D0 publication Critical patent/SE9802080D0/xx
Priority to ES99930089T priority patent/ES2205845T3/es
Priority to US09/445,571 priority patent/US6348447B1/en
Priority to AU46697/99A priority patent/AU738994B2/en
Priority to RU2000133249/14A priority patent/RU2226402C2/ru
Priority to JP2000553128A priority patent/JP2002517468A/ja
Priority to PL343104A priority patent/PL198802B1/pl
Priority to PT99930089T priority patent/PT1094834E/pt
Priority to EP20030024624 priority patent/EP1405642A1/en
Priority to CZ20004491A priority patent/CZ300873B6/cs
Priority to DE69912434T priority patent/DE69912434T2/de
Priority to DK99930089T priority patent/DK1094834T3/da
Priority to AT99930089T priority patent/ATE252912T1/de
Priority to CA2321700A priority patent/CA2321700C/en
Priority to HU0103147A priority patent/HUP0103147A3/hu
Priority to NZ506163A priority patent/NZ506163A/en
Priority to PCT/SE1999/000997 priority patent/WO1999064060A1/en
Priority to EP99930089A priority patent/EP1094834B1/en
Priority to ZA200004080A priority patent/ZA200004080B/xx
Priority to NO20006194A priority patent/NO327738B1/no
Priority to JP2010151403A priority patent/JP2010270125A/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
SE9802080A 1998-06-11 1998-06-11 Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein SE9802080D0 (sv)

Priority Applications (21)

Application Number Priority Date Filing Date Title
SE9802080A SE9802080D0 (sv) 1998-06-11 1998-06-11 Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
EP99930089A EP1094834B1 (en) 1998-06-11 1999-06-08 Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
EP20030024624 EP1405642A1 (en) 1998-06-11 1999-06-08 Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
DE69912434T DE69912434T2 (de) 1998-06-11 1999-06-08 Pharmazeutische zusammensetzung zur behandlung einer funktionalen dyspepsie und/oder des reizdarmsyndroms und die verwendung neuer substanzen in dieser zusammensetzung
AU46697/99A AU738994B2 (en) 1998-06-11 1999-06-08 Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
RU2000133249/14A RU2226402C2 (ru) 1998-06-11 1999-06-08 Фармацевтическая композиция для лечения функциональной диспепсии и/или синдрома раздраженной толстой кишки и новое применение веществ в ней
JP2000553128A JP2002517468A (ja) 1998-06-11 1999-06-08 機能性消化不良および／または過敏性腸症候群の治療用の医薬組成物ならびにその中の物質の新規な使用
PL343104A PL198802B1 (pl) 1998-06-11 1999-06-08 Zastosowanie żołądkowo-jelitowego hormonu peptydowego oraz kompozycja farmaceutyczna do leczenia funkcjonalnej dyspepsji i/lub zespołu jelita drażliwego
PT99930089T PT1094834E (pt) 1998-06-11 1999-06-08 Composicao farmaceutica para o tratamento de dispepsia funcional e/ou da sindroma do intestino irritavel e nova utilizacao de substancias contidas nessa composicao
ES99930089T ES2205845T3 (es) 1998-06-11 1999-06-08 Composicion farmaceutica para el tratamiento de dispepsia funcional y/o sindrome del intestino irritable y nuevo uso de sustancias en esta composicion.
CZ20004491A CZ300873B6 (cs) 1998-06-11 1999-06-08 Farmaceutický prostredek pro lécbu funkcní dyspepsie a/nebo syndromu dráždivého tracníku a kombinace GLP-1 se somatostatinem pro použití jako lécivo
US09/445,571 US6348447B1 (en) 1998-06-11 1999-06-08 Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
DK99930089T DK1094834T3 (da) 1998-06-11 1999-06-08 Farmaceutisk sammensætning til behandling af funktionel dybspepsi og/eller irritabel tarmsyndrom samt ny anvendelse deraf
AT99930089T ATE252912T1 (de) 1998-06-11 1999-06-08 Pharmazeutische zusammensetzung zur behandlung einer funktionalen dyspepsie und/oder des reizdarmsyndroms und die verwendung neuer substanzen in dieser zusammensetzung
CA2321700A CA2321700C (en) 1998-06-11 1999-06-08 Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
HU0103147A HUP0103147A3 (en) 1998-06-11 1999-06-08 Pharmaceutical composition comprising glp1 and their use for the treatment of functional dyspepsia and/or irritable bowel syndrome
NZ506163A NZ506163A (en) 1998-06-11 1999-06-08 Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
PCT/SE1999/000997 WO1999064060A1 (en) 1998-06-11 1999-06-08 Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
ZA200004080A ZA200004080B (en) 1998-06-11 2000-08-10 Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowels syndrome and new use of substances therein.
NO20006194A NO327738B1 (no) 1998-06-11 2000-12-06 Anvendelse av et gastrointestinalt peptidhormon eller et derivat derav samt farmasoytisk sammensetning
JP2010151403A JP2010270125A (ja) 1998-06-11 2010-07-01 機能性消化不良および／または過敏性腸症候群の治療用の医薬組成物ならびにその中の物質の新規な使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9802080A SE9802080D0 (sv) 1998-06-11 1998-06-11 Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein

Publications (1)

Publication Number Publication Date
SE9802080D0 true SE9802080D0 (sv) 1998-06-11

Family

ID=20411665

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9802080A SE9802080D0 (sv) 1998-06-11 1998-06-11 Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein

Country Status (19)

Country Link
US (1) US6348447B1 (pt)
EP (2) EP1405642A1 (pt)
JP (2) JP2002517468A (pt)
AT (1) ATE252912T1 (pt)
AU (1) AU738994B2 (pt)
CA (1) CA2321700C (pt)
CZ (1) CZ300873B6 (pt)
DE (1) DE69912434T2 (pt)
DK (1) DK1094834T3 (pt)
ES (1) ES2205845T3 (pt)
HU (1) HUP0103147A3 (pt)
NO (1) NO327738B1 (pt)
NZ (1) NZ506163A (pt)
PL (1) PL198802B1 (pt)
PT (1) PT1094834E (pt)
RU (1) RU2226402C2 (pt)
SE (1) SE9802080D0 (pt)
WO (1) WO1999064060A1 (pt)
ZA (1) ZA200004080B (pt)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4713798B2 (ja) 1999-06-29 2011-06-29 マンカインド コーポレイション ペプチドおよびタンパク質の薬学的因子の精製および安定化
US9006175B2 (en) * 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
US6579851B2 (en) 2000-03-14 2003-06-17 Amylin Pharmaceuticals, Inc. Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility
AU2001263230B2 (en) * 2000-05-19 2005-03-10 Amylin Pharmaceuticals, Llc Treatment of acute coronary syndrome with glp-1
EP2990417A1 (en) 2001-12-21 2016-03-02 Human Genome Sciences, Inc. Albumin insulin fusion protein
MXPA04008068A (es) 2002-02-20 2004-11-26 Lilly Co Eli Metodo para administrar moleculas de glp-1.
ES2300568T3 (es) 2002-03-20 2008-06-16 Mannkind Corporation Aparato de inhalacion.
US20080260838A1 (en) * 2003-08-01 2008-10-23 Mannkind Corporation Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
BRPI0411132B8 (pt) 2003-06-12 2021-05-25 Lilly Co Eli protéina de fusão heteróloga e seus usos
EP2210612B1 (en) 2003-06-18 2016-10-05 Ocera Therapeutics, Inc. Macrocyclic antagonists of the motilin receptor
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
MX2007001903A (es) 2004-08-20 2007-08-02 Mannkind Corp Catalisis de sintesis de dicetopiperazina.
DK1791542T3 (en) 2004-08-23 2015-06-15 Mannkind Corp Diketopiperazinsalte for pharmaceutical delivery
EP1874339A1 (en) * 2005-04-21 2008-01-09 Gastrotech Pharma A/S Pharmaceutical preparations of a glp-1 molecule and an anti-emetic drug
EA012442B1 (ru) 2005-05-13 2009-10-30 Эли Лилли Энд Компани Пегилированные соединения glp-1
AR055346A1 (es) 2005-06-30 2007-08-22 Sod Conseils Rech Applic Composiciones farmaceuticas de glp -1
CA2617049A1 (en) * 2005-07-29 2007-03-08 Ziopharm Oncology, Inc. Compounds and methods for the treatment of cancer
CA2621806C (en) 2005-09-14 2016-08-02 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
CN101389348A (zh) 2006-02-22 2009-03-18 曼金德公司 用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法
MX2009006942A (es) * 2006-12-29 2009-11-09 Ipsen Pharma Sas Composiciones farmaceuticas de glp-1.
WO2008134425A1 (en) * 2007-04-27 2008-11-06 Cedars-Sinai Medical Center Use of glp-1 receptor agonists for the treatment of gastrointestinal disorders
KR20100090692A (ko) * 2007-10-24 2010-08-16 맨카인드 코포레이션 활성제의 전달
US8785396B2 (en) 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
EP2211842B1 (en) * 2007-10-24 2015-08-12 MannKind Corporation An inhalable dry powder formulation comprising glp-1 for use in the treatment of hyperglycemia and diabetes by pulmonary administration
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
EP3281663B8 (en) 2008-06-13 2022-09-21 MannKind Corporation Breath powered dry powder inhaler for drug delivery
AU2009261441B2 (en) 2008-06-17 2013-01-10 Glytech, Inc. Oligosaccharide chain added glp-1 peptide
ES2421385T3 (es) 2008-06-20 2013-09-02 Mannkind Corp Aparato interactivo y procedimiento para establecer el perfil, en tiempo real, de esfuerzos de inhalación
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
EP2216042A1 (en) 2009-02-09 2010-08-11 Ipsen Pharma S.A.S. GLP-1 analogues pharmaceutical compositions
WO2010105094A1 (en) 2009-03-11 2010-09-16 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
US8614185B2 (en) 2009-05-04 2013-12-24 Centocor Ortho Biotech Inc. Fusion proteins of alpha-MSH derivatives and Fc
WO2010129248A1 (en) 2009-05-06 2010-11-11 Centocor Ortho Biotech Inc. Melanocortin receptor binding conjugates
ES2943333T3 (es) 2009-06-12 2023-06-12 Mannkind Corp Micropartículas de dicetopiperazina con superficies específicas definidas
CA2769013C (en) * 2009-07-29 2015-04-07 Daiichi Sankyo Company, Limited Motilin-like peptide compound having transmucosal absorbability imparted thereto
EP2495255A4 (en) 2009-10-30 2013-05-15 Otsuka Chemical Co Ltd GLYCOSYLATED FORM OF AN ANTIGENIC GLP-1 ANALOG
EP2496295A1 (en) 2009-11-03 2012-09-12 MannKind Corporation An apparatus and method for simulating inhalation efforts
EP2555791B1 (en) * 2010-04-09 2017-11-01 Sinai Health System Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
CA2797133C (en) 2010-04-27 2019-08-06 Zealand Pharma A/S Peptide conjugates of glp-1 receptor agonists and gastrin and their use
CA2801936C (en) 2010-06-21 2021-06-01 Mannkind Corporation Dry powder drug delivery system and methods
WO2012000118A1 (en) 2010-07-02 2012-01-05 Angiochem Inc. Short and d-amino acid-containing polypeptides for therapeutic conjugates and uses thereof
EP3326620B1 (en) 2010-12-16 2020-03-04 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2- hydroxybenzoyl)amino)caprylic acid
CN105667994B (zh) 2011-04-01 2018-04-06 曼金德公司 用于药物药盒的泡罩包装
HUE031405T2 (en) 2011-04-12 2017-07-28 Novo Nordisk As Double-acylated GLP-1 derivatives
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
KR20140095483A (ko) 2011-10-24 2014-08-01 맨카인드 코포레이션 통증을 치료하기 위한 방법 및 조성물
EA028951B9 (ru) 2011-11-03 2018-05-31 Зилэнд Фарма А/С Пептидные конъюгаты агониста рецептора гастрина и глюкагон подобного пептида 1
TR201903918T4 (tr) 2012-03-22 2019-04-22 Novo Nordisk As Bir dağıtım ajanı içeren bileşimler ve bunların hazırlanması.
KR102072202B1 (ko) 2012-03-22 2020-01-31 노보 노르디스크 에이/에스 Ｇｌｐ-1 펩티드의 조성물 및 그것의 제조
RS64942B1 (sr) 2012-03-22 2024-01-31 Novo Nordisk As Kompozicije koje obuhvataju sredstvo za isporuku i njihova priprema
JP6517690B2 (ja) 2012-06-20 2019-05-22 ノヴォ ノルディスク アー／エス ペプチド及び送達剤を含む錠剤製剤
CN104619369B (zh) 2012-07-12 2018-01-30 曼金德公司 干粉药物输送系统和方法
DK2875043T3 (en) 2012-07-23 2017-03-27 Zealand Pharma As glucagon
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
US10421729B2 (en) 2013-03-15 2019-09-24 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
CN114848614A (zh) 2013-07-18 2022-08-05 曼金德公司 热稳定性干粉药物组合物和方法
CA2920488C (en) 2013-08-05 2022-04-26 Mannkind Corporation Insufflation apparatus and methods
CN104371019B (zh) 2013-08-13 2019-09-10 鸿运华宁（杭州）生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
MY176022A (en) 2013-10-17 2020-07-21 Boehringer Ingelheim Int Acylated glucagon analogues
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
JP6682432B2 (ja) 2013-11-06 2020-04-15 ジーランド ファーマ アクティーゼルスカブ Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
EA035688B1 (ru) 2013-11-06 2020-07-27 Зилэнд Фарма А/С Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
US10253078B2 (en) 2014-10-29 2019-04-09 Zealand Pharma A/S GIP agonist compounds and methods
KR101825048B1 (ko) 2014-12-31 2018-02-05 주식회사 제넥신 GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도
EP3257524B1 (en) 2015-02-11 2020-08-26 Gmax Biopharm LLC Stabilized solution preparation of pharmaceutical glp-1r antibody fusion protein
KR20170137198A (ko) 2015-04-16 2017-12-12 질랜드 파마 에이/에스 아실화된 글루카곤 유사체
DK3551651T3 (da) 2016-12-09 2024-05-13 Zealand Pharma As Acylerede glp-1/glp-2-dobbeltagonister
TWI804571B (zh) 2018-02-02 2023-06-11 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑及n-(8-(2-羥苯甲醯基)胺基)辛酸之鹽的固體組成物
CN117003874A (zh) 2018-03-20 2023-11-07 鸿运华宁（杭州）生物医药有限公司 Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
CN112521501A (zh) 2019-09-18 2021-03-19 鸿运华宁（杭州）生物医药有限公司 Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY147327A (en) * 1995-06-29 2012-11-30 Novartis Ag Somatostatin peptides
US5994500A (en) * 1996-07-19 1999-11-30 1149336 Ontario Inc. Antagonists of intestinotrophic GLP-2 peptides

Also Published As

Publication number Publication date
NZ506163A (en) 2004-10-29
HUP0103147A3 (en) 2002-02-28
NO20006194L (no) 2001-01-25
US6348447B1 (en) 2002-02-19
PT1094834E (pt) 2004-03-31
DE69912434D1 (de) 2003-12-04
AU4669799A (en) 1999-12-30
NO327738B1 (no) 2009-09-14
CZ300873B6 (cs) 2009-09-02
EP1405642A1 (en) 2004-04-07
ES2205845T3 (es) 2004-05-01
DK1094834T3 (da) 2004-01-05
WO1999064060A1 (en) 1999-12-16
ATE252912T1 (de) 2003-11-15
EP1094834B1 (en) 2003-10-29
NO20006194D0 (no) 2000-12-06
PL343104A1 (en) 2001-07-30
CA2321700A1 (en) 1999-12-16
AU738994B2 (en) 2001-10-04
JP2010270125A (ja) 2010-12-02
CA2321700C (en) 2011-05-03
DE69912434T2 (de) 2004-05-06
RU2226402C2 (ru) 2004-04-10
JP2002517468A (ja) 2002-06-18
HUP0103147A2 (hu) 2002-01-28
ZA200004080B (en) 2001-12-24
EP1094834A1 (en) 2001-05-02
PL198802B1 (pl) 2008-07-31
CZ20004491A3 (en) 2001-05-16

Similar Documents

Publication Publication Date Title
SE9802080D0 (sv) Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
RU2000133249A (ru) Фармацевтическая композиция для лечения функциональной диспепсии и/или синдрома раздраженной толстой кишки и новое применение веществ в ней
NZ334270A (en) Glucagon like peptide (GLP-1), analogs and derivatives to treat post surgical catabolic changes and insulin resistance
ATE209923T1 (de) Pharmazeutische zusammensetzungen, welche ausgewählte lanthankarbonathydrate enthalten
EA200100289A1 (ru) Способ введения инсулинотропных пептидов
WO2001068112A3 (en) Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility
WO2003018516A3 (en) Glucagon-like peptide-1 analogs
EP1992641A3 (en) GLP-1 analogues
HUP0301212A3 (en) Use of glucagon-like peptide-1 analogs for preparation pharmaceutical compositions and for treating diabetes
NO984005D0 (no) Anvendelse av et farmas°ytisk preparat som omfatter et appetittundertrykkende peptid
ZA975866B (en) Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases.
PT758241E (pt) Utilizacao de certos derivados de acido metanobisfosfonico para impedir o desprendimento de proteses e a migracao de proteses
BR9809951A (pt) Método para tratamento da obesidade
DK0470117T3 (da) Anvendelse af "calcitonin gene-related peptides" til fremstilling af lægemidler til behandling af erektile dysfunktioner
IS4510A (is) Peptíð p277 hliðstæður og lyfjasamsetningar sem innihalda þær, til meðhöndlunar eða sjúkdómsgreiningar á sykursýki
DE69011618D1 (de) Mundzubereitung zur verabreichung an bestimmter stelle des darmes.
AU3733295A (en) Treatment of obstructive airway disease by administering thymosin beta 4, or coadministration of thymosin beta 4 and dnase i
BG104139A (en) Diabetes treatment with thizolidindion and sulphonylurea
EP0797994A3 (en) Use of one or more 5-HT2 receptor antagonists in the manufacture of a medicament for treating the symptoms of venomous bites and stings
EP0384302A3 (en) Use of ubenimex in the manufacture of a medicament for treating myelodysplastic syndrome
SE8501203D0 (sv) Mammal intestinal hormone precursor and its use
WO1998024421A3 (en) Use of dextrin sulphate for the treatment of highly vascular tumours
PT1103270E (pt) Tratamento de doencas auto-imunes em mamiferos
MD1568F1 (en) Method of treatment of the burn disease in the burn shock period
ECSP993116A (es) Procedimiento para administrar peptidos insulinotropicos